Filtered By:
Source: CardioBrief
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 307 results found since Jan 2013.
Entresto Gets Boost in Updated HF Guidelines
–Valsartan/sacubitril earns Class I recommendation Cardiology groups in the U.S. and Europe have updated their heart failure guidelines to include much-awaited recommendations for Entresto (the combination of valsartan and sacubitril manufactured by Novartis). The new guidelines offer broad support for the new drug. Since its approval last summer Entresto has struggled to gain a foothold...Click here to continue reading...
Source: CardioBrief - May 20, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Policy & Ethics Entresto guidelines LCZ Source Type: blogs
On Road To Bankruptcy A Stent Company Invested in Marty Leon’s VC Fund
More questions are being raised about the research and financial activities of Palmaz Scientific, the bankrupt medical device company founded by Julio Palmaz, the co-inventor of the stent. In the middle of severe financial troubles that eventually brought the company to bankruptcy Palmaz Scientific found enough money to invest in a venture capital fund. The VC Fund,...Click here to continue reading...
Source: CardioBrief - May 3, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Uncategorized bankruptcy grooved stent Martin Leon Palmaz Palmaz Scientific Triventures Source Type: blogs
Stent Pioneer’s Company In Bankruptcy And Under Investigation
–Julio Palmaz hasn’t been able to recreate his earlier success A company founded by stent pioneer Julio Palmaz has declared bankruptcy and is being investigated for misconduct, according to the San Antonio Express-News. Palmaz, along with Richard Schatz, was the inventor of the enormously successful Palmaz-Schatz stent marketed by Johnson & Johnson. In March Palmaz...Click here to continue reading...
Source: CardioBrief - April 25, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics bankruptcy Palmaz Palmaz Scientific SEC stents Source Type: blogs
PNAS Paper By Prominent Cardiologist And Dean Retracted
A 2002 PNAS paper has been retracted by its authors, including senior author Pascal Goldschmidt, a prominent cardiologist and Dean of the University of Miami School of Medicine. News of the retraction was reported by Retraction Watch on Tuesday. The paper, “Deficient Smad7 expression: A putative molecular defect in scleroderma,”has been cited 198 times, Retraction Watch reported. Here is...Click here to continue reading...
Source: CardioBrief - April 6, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Goldschmidt Retraction Watch retractions scientific misconduct Source Type: blogs
After a Decade, CABG Pulls Ahead of Meds for HF
–Life-saving benefit of CABG now clear in long-term trial follow-up Finally, after 10 years of follow-up, the life-saving benefits of coronary artery bypass graft (CABG) surgery in heart failure patients with coronary artery disease are clear. More than 15 years ago, the NIH funded the original STICH trial to answer a question that was already...Click here to continue reading...
Source: CardioBrief - April 4, 2016 Category: Cardiology Authors: Larry Husten Tags: Heart Failure Interventional Cardiology & Surgery People, Places & Events CABG coronary artery disease STICH STICHES Source Type: blogs
Shedding Light On The Hearts Of Pro Basketball Players
Every time an athlete dies on the field there is renewed interest in the controversial topic of preparticipation screening. One key limitation in the field is that there is little or no good data about what constitutes a healthy heart in athletes. Now a new study published in JAMA Cardiology provides an extraordinarily detailed look...Click here to continue reading...
Source: CardioBrief - February 29, 2016 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes athlete's heart athletes Echocardiography Hypertrophic cardiomyopathy Marfan NBA SCD screening Source Type: blogs
At the FDA Rob Califf Will Champion Clinical Trials
Everyone wants to know what Rob Califf is going to do at the FDA. His critics say he’s going to hand the car keys over to industry and allow them to drive the agenda. Or, as one reporter tweeted: Hey, is that the sound of the FDA approving things faster? Must be because the Senate...Click here to continue reading...
Source: CardioBrief - February 25, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery People, Places & Events Policy & Ethics Califf FDA Source Type: blogs
Vulnerable Plaque: The Paradigm That Failed
Is it a hallowed paradigm or a hype-othesis? The “holy grail” of cardiology is to stop heart attacks before they happen by identifying– quickly, noninvasively, and specifically– those coronary artery lesions that result in heart attacks. The key theoretical underpinning driving this goal has been the vulnerable plaque hypothesis, which holds that the vast majority...Click here to continue reading...
Source: CardioBrief - February 24, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Policy & Ethics Prevention, Epidemiology & Outcomes stents vulnerable plaque Source Type: blogs
Massachusetts Senator Places Hold On Califf’s FDA Nomination
(Updated) US Senator Edward Markey, a Democrat from Massachusetts, is seeking to block Rob Califf’s nomination to head the FDA, according to a report in the Boston Globe. Markey will use Senate rules to place a hold on the nomination. In September President Obama nominated Califf, a well-known Duke University cardiologist and clinical researcher, to...Click here to continue reading...
Source: CardioBrief - January 25, 2016 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Califf FDA Senate Source Type: blogs
Some Come To Bury The Stethoscope, Some To Praise It
Is the stethoscope still an essential tool of modern medicine or is it an obsolete low-tech vestige of an antiquated era? There is, to say the least, a wide variety of opinions on the topic. On the one hand, technology enthusiasts argue that the stethoscope should be replaced by portable ultrasound devices. “The stethoscope’s 200th birthday should...Click here to continue reading...
Source: CardioBrief - January 15, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Cardiology medical education stethoscope technology ultrasound Source Type: blogs
Study Shows Why Sham Controls Are Necessary For Device Trials
— If we can melt the ice-caps then surely we can understand our own fallibility, says one UK cardiologist. The strongest known force in the universe is the ability of the human mind to deceive itself. If we know something to be true then we find the evidence to prove it. There is no better...Click here to continue reading...
Source: CardioBrief - January 12, 2016 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Policy & Ethics Prevention, Epidemiology & Outcomes bias blood pressure hypertension renal denervation SYMPLICITY Source Type: blogs
2015: The Year We Finally Cured Heart Disease!
Editor’s note: Larry was too depressed to write the 2015 yearly review. Veteran healthcare journalist and eternal optimist Candide Corn volunteered to take over the task this year. Candide’s motto is “all is for the best in the best of all possible worlds.” What a great year for cardiology! The year brought us an unending...Click here to continue reading...
Source: CardioBrief - December 28, 2015 Category: Cardiology Authors: Larry Husten Tags: Uncategorized Source Type: blogs
Prepublish or Perish? Making a Case for Medicine to Take a Cue from Basic Science
It’s time for clinical research to join other scientific fields like physics and computer science and encourage preprint publication of manuscripts on the internet, according to three top cardiologists writing in a Lancet comment. Since 1969 researchers have labored under the constraints of the Ingelfinger rule, in which “posting a paper, data, or key findings on the internet represented presubmission...Click here to continue reading...
Source: CardioBrief - December 17, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics journals publications preprints Source Type: blogs
Pioneering Cardiologist George Diamond Dead At 74
George Diamond, a pioneering cardiologist at the Cedars-Sinai Medical Center in Los Angeles, died on Saturday at the age of 74 from complications related to colon cancer. Here are some reactions to news of his death from several of his long-time friends and colleagues at Cedars-Sinai. Sanjay Kaul: “I am deeply saddened at the loss...Click here to continue reading...
Source: CardioBrief - December 13, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events George Diamond Source Type: blogs
Survey: Docs Think Cardiologists Are Rude, Dismissive, And Aggressive
Nearly a third of English doctors report that they are subject to rude, dismissive and aggressive (RDA) behavior more than once a week. Cardiologists are among the specialists who are most likely to be responsible for this “workplace incivility.” These are some of the chief findings of a survey published in Clinical Medicine of 606 British doctors at three...Click here to continue reading...
Source: CardioBrief - December 7, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics bad behavior cardiologists rude survey Source Type: blogs
